【摘要】 目的比较观察免疫组化(IHC)法检测乳腺癌组织中HER-2蛋白表达和荧光原位杂交(FISH)法检测其HER-2基因扩增在乳腺癌分子靶向治疗中的临床意义。方法采用IHC法及FISH法分别检测111例乳腺癌组织中HER-2蛋白表达及HER-2基因扩增情况。结果 111例乳腺癌标本中,HER-2蛋白(+++)者53例,(++)者47例,(+)或(-)者11例;基因扩增74例,未扩增37例。2种检测结果呈正相关关系(rs=0.625,P<0.05)。结论 IHC法检测HER-2蛋白可作为乳腺癌患者是否应用赫赛汀的初筛,HER-2蛋白表达阳性的患者有必要进一步进行HER-2基因扩增检测,来确定临床治疗是否应用赫赛汀。更多还原

【Abstract】 Objective To explore the clinical significance of HER-2 protein expression detected by immunohistochemistry( IHC) and HER-2 gene amplification detected by fluorescence in situ hybridization( FISH) in molecular targeting therapy of breast cancer. Methods The HER-2 protein expressions and the HER-2 gene amplification in the 111 cases of breast cancer tissues were detected by IHC and FISH,respectively. Results The numbers of patients showed IHC( +++),IHC( +++) and IHC( + /-) were 53 cases,47 cases and 11 cases,respectively. The HER-2 gene amplification existed in the 74 cases,no amplification existed in the 37 cases. There was positive correlation between the two results( rs= 0. 625,P < 0. 05). Conclusion Before herceptin therapy,the immunohistochemistry can be first used to detect the HER-2 protein expressions,and then in the cases woth positive expressions of HER-2,the HER-2gene amplifications should be further tested to guide the herceptin therapy in the treatment of breast cancer.更多还原